The development and progression of low-grade serous ovarian carcinoma

Low-grade serous ovarian carcinoma (LGSOC) is found more frequently than high-grade serous ovarian carcinoma in younger women. This rare subtype represents about 5–10% of all serous ovarian cancers and is not as sensitive to chemotherapy as high-grade serous cancer. New alternative treatments are emerging from recent clinical trials, and additional clinical trials confirming the clinical benefit of these treatments are ongoing. However, a lack of deep understanding of the development and progression of LGSOC is a major bottleneck in the development of novel therapeutic strategies. This review summarizes our current understanding of the progression and development of LGSOC, including findings from recent genomic and proteomic studies. Continuing to investigate the origins of LGSOC, including its potential precursors, will enable us to develop strategies to inhibit the development and progression of this devastating disease.